Literature DB >> 11410275

Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.

R A Bonomo1, J Liu, Y Chen, L Ng, A M Hujer, V E Anderson.   

Abstract

The CMY-2 beta-lactamase, a plasmid determined class C cephalosporinase, was shown to be susceptible to inhibition by tazobactam (K(i)=40 microM). The reaction product(s) of CMY-2 beta-lactamase with the beta-lactamase inhibitor tazobactam were analyzed by electrospray ionization/mass spectrometry (ESI/MS) to characterize the prominent intermediates of the inactivation pathway. The ESI/MS determined mass of CMY-2 beta-lactamase was 39851+/-3 Da. After inactivating CMY-2 beta-lactamase with excess tazobactam, a single species, M(r)=39931+/-3.0, was detected. Comparison of the peptide maps from tryptic digestion of the native enzyme and the inactivated beta-lactamase followed by LC/MS identified two 22 amino acid peptides containing the active site Ser64 modified by a fragment of tazobactam. These two peptides were increased in mass by 70 and 88 Da, respectively. UV difference spectra following inactivation revealed the presence of a new species with a 302 nm lambda(max). Based upon the increase in molecular mass of the tazobactam inactivated CMY-2 beta-lactamase, we propose that during the inactivation of this beta-lactamase by tazobactam an imine is formed. Tautomerization forms the spectrally observed enamine. Hydrolysis generates the covalently attached malonyl semialdehyde, its hydrate, or an enol. This work provides information on the mass of a stable enzyme intermediate of a class C beta-lactamase inactivated by tazobactam and, for the first time, unequivocal evidence that a cross-linked species is not required for apparent inactivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410275     DOI: 10.1016/s0167-4838(01)00175-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

2.  N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Authors:  Marion J Skalweit; Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

3.  Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.

Authors:  Pius S Padayatti; Anjaneyulu Sheri; Monica A Totir; Marion S Helfand; Marianne P Carey; Vernon E Anderson; Paul R Carey; Christopher R Bethel; Robert A Bonomo; John D Buynak; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2006-10-11       Impact factor: 15.419

4.  Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry.

Authors:  Hilary Frase; Clyde A Smith; Marta Toth; Matthew M Champion; Shahriar Mobashery; Sergei B Vakulenko
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

5.  Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam.

Authors:  Michiyoshi Nukaga; Krisztina M Papp-Wallace; Tyuji Hoshino; Scott T Lefurgy; Christopher R Bethel; Melissa D Barnes; Elise T Zeiser; J Kristie Johnson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid.

Authors:  Hilary Frase; Marta Toth; Matthew M Champion; Nuno T Antunes; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

7.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

8.  Penicillin sulfone inhibitors of class D beta-lactamases.

Authors:  Sarah M Drawz; Christopher R Bethel; Venkata R Doppalapudi; Anjaneyulu Sheri; Sundar Ram Reddy Pagadala; Andrea M Hujer; Marion J Skalweit; Vernon E Anderson; Shu G Chen; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

10.  New method for laboratory detection of AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae.

Authors:  K Nasim; S Elsayed; J D D Pitout; J Conly; D L Church; D B Gregson
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.